NCT04796948已完成1 期
A Phase I Study to Evaluate the Safety and Tolerability of Irinotecan Liposome in Combination With Oxaliplatin and 5-FU/LV in the Treatment of Advanced Pancreatic Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 41
- 试验地点
- 1
- 主要终点
- MTD
研究概览
简要总结
To determine the safety and tolerability of irinotecan liposome in combination with oxaliplatin and 5-FU/LV in subjects with advanced pancreatic cancer who have not received prior systemic chemotherapy
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and females aged 18 to 70 years (including 18 and 70 years);
- •Patients with histologically or cytologically diagnosed pancreatic cancer (from pancreatic ductal epithelium), and clinical records show unresectable locally advanced or metastatic pancreatic cancer (stage III/IV based on the 8th Edition of the AJCC TNM staging for pancreatic cancer).
- •Have not received systemic anti-tumor therapy for the current stage of disease, including surgery (except stent placement), radiotherapy, chemotherapy, targeted therapy, immunotherapy or investigational therapy;
- •If the subject has previously received adjuvant chemotherapy, it is necessary to ensure that the time interval between the last dose and the first dose of this study is more than 12 months, and the adjuvant therapy-toxicity has recovered (judged as ≤ grade 1 based on CTCAE 5.0 criteria);
- •Must have at least one measurable lesion that can be taken as the target lesion (according to the RECIST v1.1 criteria);
- •Eastern Cooperative Oncology Group (ECOG) performance status score: 0 - 1 point;
- •Expected survival ≥3 months;
- •Major organs are functioning well
排除标准
- •Patients with pancreatic cancer originating from extrapancreatic ductal epithelium, including pancreatic neuroendocrine carcinoma, acinar cell carcinoma of the pancreas, pancreatoblastoma, and solid-pseudopapillary tumor;
- •Patients with known central nervous system metastases;
- •Patients carrying homozygous mutations of UGT1A1*28/*6 gene;
- •Severe gastrointestinal dysfunction;
- •Severe infection (> CTCAE grade 2), such as severe pneumonia, bacteremia, infection complications, etc. requiring inpatient treatment, occurred within four weeks before enrollment, and symptoms and signs of infection requiring intravenous antibiotic therapy (except for prophylactic antibiotics) occurred within two weeks before enrollment;
- •Received any of the following treatments:
- •1）Previously received treatment with irinotecan-containing regimens; 2）Received concomitant medications containing strong inhibitors/strong inducers of CYP3A4 or strong inhibitors of UGT1A1 within two weeks before enrollment; 3）Received the last anti-cancer treatment (including surgery, radiotherapy, etc.) within four weeks before enrollment; 4）Have received treatment with any other investigational drug/device within four weeks before enrollment; 5）Enrolled in another clinical study at the same time unless it is an observational (non-interventional) clinical study or an interventional clinical study follow-up.
- •7.Having experienced an arteriovenous thrombotic event, such as cerebrovascular accident, deep vein thrombosis and pulmonary embolism, within one year before enrollment; 8.Patients with cardiac clinical symptoms or diseases that are not well controlled, such as: (1) Patients with NYHA class 2 and above cardiac failure; (2) unstable angina; (3) myocardial infarction that occurred within one year; (4) clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention.
- •9.Patients who have suffered from malignant tumors other than pancreatic cancer before using the study drug for the first time, except those with low risk of metastasis and death (5-year survival rate >90%), such as adequately treated cervical carcinoma in situ, basal cell or squamous cell carcinoma of the skin; 10.Have any contraindication to either irinotecan liposome, irinotecan, 5-FU, calcium folinate, or oxaliplatin;
研究组 & 干预措施
Irinotecan liposome；oxaliplatin；5-FU(Fluorouracil Injection)；LV(Calcium Folinate Injection)
Experimental
- irinotecan liposome: irinotecan liposome injection is irinotecan encapsulated in liposomes for i.v. infusion.
- oxaliplatin: oxaliplatin is a sterile, aqueous solution; 50mg/vial.
- 5-FU(Fluorouracil Injection): an aqueous, sterile, nonpyrogenic injectable solution available in 10ml/0.25g.
- LV(Calcium Folinate Injection): be supplied in vials containing 10ml/0.1g and available as an injectable solution.
干预措施: Irinotecan liposome；oxaliplatin；5-FU(Fluorouracil Injection)；LV(Calcium Folinate Injection) (Drug)
结局指标
主要结局
MTD
时间窗: 18 months
Maximum tolerated dose for patients in combination treatment.
RP2D
时间窗: 18 months
Recommended phase II dose for patients in combination treatment.
次要结局
- Frequency and severity of AEs/SAEs as Assessed by CTCAE v5.0(From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months.)
- Objective Response Rate (ORR)(From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months.)
- Disease Control Rate (DCR)(From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months)
- Cmax(28days)
- Tmax(28days)
- Progression-Free Survival (PFS)(From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months.)
- Overall Survival (OS)(From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months.)
- AUC(28days)
- t1/2z(28days)
- Vss(28days)
- CL(28days)
- Duration of Response (DoR)(From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic CancerPancreatic NeoplasmsNeoplasm MetastasisHepatic Metastasis of Pancreatic CancerNCT06538623Ruijin Hospital40
已完成
1 期
Study of Irinotecan Liposome Injection in Patients With Advanced Breast CanceAdvanced Breast CancerNCT04728035CSPC Ouyi Pharmaceutical Co., Ltd.119
尚未招募
2 期
Irinotecan Liposome for Resectable Pancreatic Cancer With or Without AddebelizumabNeoadjuvant ChemotherapyResectable Pancreatic CancerNCT06172036Zhejiang University180
Unknown
1 期
A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal CancerMetastatic CancerColorectal AdenocarcinomaColorectal CancerNCT04380103Chinese Academy of Medical Sciences106
招募中
2 期
NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory StudyBorderline Resectable Pancreatic CancerNCT06345300Cancer Institute and Hospital, Chinese Academy of Medical Sciences40